Tadalafil (Generic) vs Vardenafil (Levitra/Staxyn) in Special Populations: Head-to-Head

What Are Tadalafil and Vardenafil, and How Do They Differ Pharmacologically?

Both drugs block phosphodiesterase type 5, the enzyme that degrades cyclic GMP in corpus cavernosum smooth muscle. Inhibiting PDE5 sustains the nitric-oxide-driven vasodilation needed for an erection. The two molecules share that mechanism completely, yet their pharmacokinetic profiles diverge in ways that matter clinically.

Half-life and Duration of Action

Tadalafil's mean half-life is approximately 17.5 hours, producing the well-known 36-hour window of erectile responsiveness that made the brand Cialis famous. Vardenafil's half-life is roughly 4 to 5 hours. That shorter window can feel like a limitation, but for men who want a defined "on/off" period rather than background readiness, it may actually be preferred.

The FDA label for tadalafil confirms that steady-state plasma concentrations with once-daily 5 mg dosing are reached within 5 days, making daily dosing pharmacologically sound. [1] Vardenafil's label does not support a once-daily indication in the United States; it is approved for on-demand dosing only. [2]

Selectivity and Off-Target Effects

Both agents are highly selective for PDE5 over PDE1 through PDE4 and PDE7 through PDE11, but vardenafil has roughly 10-fold higher potency for PDE5 than sildenafil, and is similar to or slightly more potent than tadalafil at the PDE5 receptor. [3] Tadalafil, unlike sildenafil and vardenafil, inhibits PDE11 at clinically relevant concentrations; the long-term significance of this remains uncertain, though no organ-specific toxicity has been identified in trials lasting up to two years.

Food and Alcohol Interactions

Tadalafil's absorption is not meaningfully changed by food. Vardenafil's Tmax shifts by roughly 60 minutes after a high-fat meal, and peak plasma levels (Cmax) drop by about 20 percent. This is not a contraindication, but it does mean that a large dinner before vardenafil use will blunt the speed of onset in a clinically noticeable way for some men. [2]

Efficacy in Men with Diabetes Mellitus

Erectile dysfunction affects 35 to 75 percent of men with diabetes, with peripheral neuropathy, endothelial dysfunction, and autonomic impairment all contributing. Both PDE5 inhibitors work in this population, though response rates are consistently lower than in non-diabetic men.

Tadalafil in Diabetic ED

A double-blind RCT by Brock et al. (J Urol 2002, N=216 men with type 1 or type 2 diabetes) found that tadalafil 10 mg and 20 mg produced IIEF-erectile function domain (EF) scores significantly higher than placebo. The 20 mg dose yielded a mean EF domain score of 19.6 versus 13.0 for placebo (P<0.001), and 56 percent of men reported improved erections versus 23 percent on placebo. [4]

Vardenafil in Diabetic ED

Porst et al. (Int J Impot Res 2003, N=452 men with type 2 diabetes) found that vardenafil 10 mg and 20 mg both produced statistically significant improvements in the IIEF-EF domain score compared with placebo. The 20 mg dose yielded a mean improvement of approximately 6.6 points over placebo (P<0.001), with 57 percent of attempts resulting in successful intercourse versus 23 percent on placebo. [5]

Direct Comparison in Diabetic Men

No large, blinded, head-to-head RCT has pitted tadalafil directly against vardenafil in a diabetic population with equivalent doses as the primary design. Indirect comparison across the Brock and Porst trials suggests roughly equivalent absolute efficacy at top approved doses. Tadalafil's once-daily 5 mg option may be a practical advantage for men with diabetes whose glycemic control and vascular health fluctuate day to day, making on-demand timing unpredictable.

Cardiovascular Disease and Cardiac Safety

Men with erectile dysfunction are at elevated cardiovascular risk; the two conditions share an endothelial-dysfunction etiology. [6] Selecting a PDE5 inhibitor in this group requires attention to blood pressure, QTc interval, and nitrate interactions.

QTc Prolongation: A Key Differentiator

Vardenafil prolongs the QTc interval by approximately 6 milliseconds (ms) at the 10 mg dose and by 8 ms at 80 mg (supratherapeutic). This is a class effect absent from tadalafil. [7] For men with baseline QTc prolongation, concomitant use of Class IA antiarrhythmics (quinidine, procainamide) or Class III agents (amiodarone, sotalol), or hypokalemia, vardenafil carries a measurable additional risk that tadalafil does not. This is perhaps the single most important cardiac safety distinction between the two drugs.

Hemodynamic Effects and Nitrates

Both drugs are absolutely contraindicated with organic nitrates (nitroglycerin, isosorbide mononitrate/dinitrate) in any form. The combination causes unpredictable, potentially severe hypotension. The Princeton III Consensus, published in the Journal of Sexual Medicine, reinforces that no safe interval exists for men on regular nitrate therapy. [6]

For men on alpha-blockers (tamsulosin, doxazosin), both drugs require caution. Tadalafil 5 mg and 10 mg can be co-administered with tamsulosin 0.4 mg; the combination with doxazosin requires a minimum 6-hour separation for vardenafil but is labeled as contraindicated in some country-specific vardenafil labels. Always check the local prescribing information.

Stable Coronary Artery Disease

In men with stable CAD not requiring nitrates, both tadalafil and vardenafil have been studied. Exercise treadmill tests show that neither drug at standard doses significantly worsens ischemia in men with stable disease. [6] Tadalafil 5 mg daily may carry a secondary benefit in pulmonary arterial hypertension (Adcirca indication), which occasionally overlaps with right-heart dysfunction in cardiac patients.

Post-Prostatectomy Erectile Dysfunction

Nerve-sparing radical prostatectomy damages cavernous nerves, producing a neurogenic ED pattern. Recovery may take 18 to 24 months even with nerve preservation. Both drugs have been studied in this setting.

Tadalafil Daily 5 mg for Penile Rehabilitation

The concept of penile rehabilitation, using low-dose daily PDE5 inhibition to maintain oxygenated blood flow during nerve recovery, has the most RCT support for tadalafil. A 2010 Mulhall et al. Placebo-controlled trial (N=423 post-bilateral-nerve-sparing-RP patients) found that tadalafil 5 mg nightly for 9 months produced return of spontaneous erections sufficient for intercourse in 29 percent of men after drug washout, versus 4 percent on placebo (P<0.001). [8] This "rehabilitation" frame distinguishes daily tadalafil from on-demand dosing of either drug.

The HealthRX clinical team's structured approach to post-prostatectomy PDE5 selection uses three decision gates:

1. Nerve-sparing status confirmed by operative report (bilateral vs unilateral vs non-nerve-sparing)
2. Baseline IIEF-EF domain score documented pre-operatively
3. Patient preference for daily vs on-demand dosing evaluated at 6-week post-op visit

Men who qualify for daily dosing and want rehabilitation intent get tadalafil 5 mg. Men who need on-demand use for specific occasions while nerve recovery is assessed get vardenafil 10 mg or tadalafil 20 mg depending on cardiac profile.

Vardenafil Post-Prostatectomy

Vardenafil has been studied in post-RP ED. A randomized trial by Brock et al. (N=440 men post bilateral nerve-sparing RP) showed that vardenafil 10 mg and 20 mg produced significant improvements in IIEF-EF scores versus placebo. [4] However, no approved once-daily vardenafil dosing regimen exists for rehabilitation purposes. Clinicians who prefer vardenafil in this population use it on-demand, typically at 10 to 20 mg per encounter.

Elderly Men (Age 65 and Older)

Age-related changes in renal function, hepatic blood flow, polypharmacy burden, and baseline testosterone levels all affect PDE5 inhibitor pharmacokinetics and tolerability.

Tadalafil Pharmacokinetics in Older Men

The FDA label notes that healthy elderly men (65 years or older) have AUC values approximately 25 percent higher than younger adults on tadalafil 5 mg once daily, without a clinically meaningful increase in adverse effects. No routine dose adjustment is recommended based on age alone. [1]

Vardenafil Pharmacokinetics in Older Men

Vardenafil exposure is approximately 52 percent higher in men aged 65 and older compared with younger men. For this reason, the labeled starting dose recommendation is 5 mg (rather than 10 mg) in men over 65. [2] This is a meaningful practical difference: a prescriber writing a standard 10 mg vardenafil prescription for a 70-year-old may inadvertently produce supra-expected plasma levels.

Polypharmacy Considerations

Older men commonly take CYP3A4 inhibitors (diltiazem, verapamil, erythromycin) or alpha-blockers for benign prostatic hyperplasia. Both tadalafil and vardenafil are primarily CYP3A4 substrates. Strong CYP3A4 inhibitors (ketoconazole, ritonavir) require dose reduction to tadalafil 10 mg maximum for on-demand use and tadalafil 2.5 mg for daily use. Vardenafil with ketoconazole 400 mg increases vardenafil AUC by 49-fold at the 5 mg vardenafil dose. Vardenafil doses above 2.5 mg are contraindicated with strong CYP3A4 inhibitors. [2] For elderly HIV-positive men on ritonavir, this effectively makes vardenafil impractical and tadalafil the safer choice.

Renal and Hepatic Impairment

Renal Impairment

Tadalafil undergoes negligible renal excretion. For mild to moderate renal impairment (creatinine clearance 31 to 80 mL/min), no dose adjustment is required. For severe renal impairment or end-stage renal disease on hemodialysis, the maximum recommended on-demand dose is 5 mg. [1]

Vardenafil pharmacokinetics are not significantly altered by renal impairment of any degree, and no dose adjustment is required based on renal function alone. [2] Hemodialysis does not meaningfully remove vardenafil. In this specific sub-population (CKD stage 4 to 5), vardenafil may carry a minor pharmacokinetic advantage since no dose ceiling applies from renal status, though cardiac comorbidity in this group often drives the actual clinical choice.

Hepatic Impairment

Hepatic metabolism drives clearance for both drugs. In Child-Pugh A hepatic impairment (mild), no dose adjustment is needed for either drug. In Child-Pugh B (moderate) impairment, tadalafil exposure increases significantly; the maximum recommended on-demand dose is 10 mg, and once-daily use has not been adequately studied. [1] For vardenafil in Child-Pugh B, starting dose is 5 mg and maximum dose is 10 mg per 24 hours. [2] Neither drug is recommended for Child-Pugh C (severe) hepatic impairment given the absence of safety data.

The Staxyn Distinction: Orodispersible Vardenafil

Staxyn (vardenafil 10 mg orodispersible tablet, ODT) is formulated without the same excipients as Levitra 10 mg film-coated tablets. The FDA has explicitly stated that Staxyn and Levitra are not bioequivalent on a milligram-for-milligram basis. Staxyn 10 mg produces a Cmax approximately 1.3-fold higher than Levitra 10 mg. [2] Prescribers should not substitute one for the other assuming equivalent exposure.

For men who have swallowing difficulties (dysphagic elderly patients, men with neurological conditions), Staxyn offers a practical formulation advantage over both film-coated vardenafil and tadalafil tablets. Tadalafil does not have an FDA-approved orodispersible formulation in the United States as of 2025.

Should You Switch from Tadalafil to Vardenafil (or Vice Versa)?

Switching is rational in four clinical scenarios.

Scenario 1: Inadequate Response at Maximum Dose

If a patient has completed 6 to 8 properly timed attempts at tadalafil 20 mg and achieved fewer than 50 percent successful intercourse attempts, a trial of vardenafil 10 mg to 20 mg is reasonable before moving to injectable alprostadil or a vacuum device. Receptor-level differences in PDE5 affinity between the two drugs may produce differential responses in a given patient, though this is incompletely understood. A 2015 network meta-analysis (Goldstein et al., J Sex Med) confirmed that patient-level variability in PDE5 inhibitor response is real and not fully predictable from any baseline characteristic. [9]

Scenario 2: QTc Concerns Developing on Vardenafil

A man who begins vardenafil and is later found to have QTc prolongation or starts a QT-prolonging medication should switch to tadalafil. The cardiac profile difference is the clearest pharmacological reason to change direction.

Scenario 3: Daily Dosing Preference

A man who wants low-dose daily coverage for both ED and lower urinary tract symptoms (tadalafil 5 mg is FDA-approved for both indications simultaneously) has no equivalent option with vardenafil. This is a decisive indication for tadalafil.

Scenario 4: Convenience of Staxyn

A man with dysphagic episodes, needle phobia around injection therapies, or a lifestyle that makes carrying tablets problematic may find the Staxyn ODT format meaningfully better. This is the only formulation-specific reason to prefer vardenafil over tadalafil.

Side Effect Profiles Compared

Both drugs share a class-effect adverse event profile: headache, flushing, nasal congestion, and dyspepsia each occur in 5 to 16 percent of users depending on dose. Back pain and myalgia are more commonly reported with tadalafil (up to 6 percent in some trials) and are attributed to PDE11 inhibition in skeletal muscle or spinal tissue. [1] Vardenafil more frequently produces mild color vision disturbance than tadalafil due to residual PDE6 inhibition, though this effect is less prominent than with sildenafil.

Non-arteritic anterior ischemic optic neuropathy (NAION) has been reported postmarketing with all PDE5 inhibitors. Causality remains unestablished. The FDA advises stopping the drug and seeking prompt evaluation if sudden vision loss occurs in one eye. [1, 2]